Management of Hepatic Encephalopathy with Lactulose and Rifaximin

Introduction to Treatment Options

The American Association for the Study of Liver Diseases recommends lactulose as the first-line treatment for hepatic encephalopathy (HE), while rifaximin is most effective as an add-on therapy to lactulose for prevention of HE recurrence and treatment of lactulose-resistant cases 1, 2

Lactulose is recommended as the initial therapeutic option for overt hepatic encephalopathy (OHE) due to its efficacy and low cost 1, 2
Dosing should be initiated at 25-30 mL (20-30g) every 1-2 hours until the patient has at least 2 soft bowel movements per day, then titrated to maintain 2-3 bowel movements daily 1, 3
For patients unable to take medications orally, lactulose can be administered via nasogastric tube 1
In severe HE (West-Haven criteria grade 3 or higher), an enema of 300 mL lactulose and 700 mL water can be administered 3-4 times daily until clinical improvement 3
Lactulose works by converting ammonia to ammonium (making it less absorbable) and creating an osmotic laxative effect that flushes ammonia out 3
Overuse of lactulose should be avoided as it can lead to complications such as aspiration, dehydration, hypernatremia, and severe perianal skin irritation 1

Rifaximin is not recommended as monotherapy for HE; there are no solid data supporting its use alone 1
Rifaximin is most effective as an add-on therapy to lactulose in the following scenarios: for prevention of HE recurrence in patients who have experienced two or more episodes of HE 2
The combination of rifaximin and lactulose has been shown to improve recovery from HE within 10 days (76% vs. 44%) 3
The combination of rifaximin and lactulose has been shown to shorten hospital stays (5.8 vs. 8.2 days) 3
Standard rifaximin dosing is 400 mg three times daily or 550 mg twice daily 3

For initial presentation of HE, the American Association for the Study of Liver Diseases recommends starting with lactulose as first-line therapy 1, 2
For persistent or recurrent HE despite lactulose therapy, rifaximin should be added to the treatment regimen 2
For prevention of HE recurrence after two or more episodes, the American Association for the Study of Liver Diseases recommends maintaining on combination therapy of lactulose and rifaximin 2

The American Association for the Study of Liver Diseases recommends lactulose as the first choice for treatment of episodic overt hepatic encephalopathy, with a clinical response observed in approximately 75% of patients, and a reduction in blood ammonia levels by 25-50% 4, 5
Lactulose is also recommended for prevention of recurrent episodes of hepatic encephalopathy after the initial episode, with a Grade II-1, A, 1 recommendation 4, 6

Simple laxatives alone are not recommended for hepatic encephalopathy due to their lack of prebiotic properties, and lactulose is preferred as first-line therapy 4, 5
For patients who cannot tolerate lactulose, rifaximin may be considered, although evidence supports lactulose as the primary treatment option 4
In specific situations like post-TIPS hepatic encephalopathy, neither lactulose nor rifaximin has been shown to be better than placebo for prevention 4, 6